FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
What happened
FDA inspected the facility from November 3 to 7, 2025, and found CGMP deviations for active pharmaceutical ingredients (APIs). The company repackaged and relabeled semaglutide bought from suppliers not on its approved list, changed manufacturing and retest dates, named itself as manufacturer, and shipped the API to the U.S. without required drug listing. FDA also found missing process validation, inadequate cleaning validation, incomplete analytical method validation, and water-monitoring gaps; the company later recalled two semaglutide API batches.
What FDA found
The quality unit lacked procedures and oversight for repackaging and relabeling externally bought APIs, and semaglutide from unapproved suppliers was relabeled with new batch numbers and changed dates.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The company released and distributed semaglutide API to the U.S. without having conducted process validation.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Cleaning validation was inadequate because the company did not set a maximum carryover limit, justify swab locations, or provide swab test results.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Analytical test methods were not fully validated or verified before tirzepatide API was shipped, and some method validation data were inadequate.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Water used in manufacturing was not adequately monitored and controlled for total microbial counts, objectionable organisms, and endotoxins.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The company failed to list relabeled semaglutide and falsely labeled itself as manufacturer instead of the actual manufacturers.
FD&C Act sections 510(j), 502(a), 502(b)(1), and 502(o); 21 CFR Part 207
What FDA wants
FDA asks the company to provide risk assessments, CAPA plans, process and cleaning validation, analytical method validation, water-system monitoring, stability data, and customer notification and recall determinations. The provided letter does not state a response deadline.
Who should pay attention
- U.S. compounding pharmacies and clinics buying GLP-1 APIs
- brands and distributors sourcing semaglutide or tirzepatide API overseas
- supplier quality teams managing API repackagers and relabelers
This is a summary. Read the original letter on fda.gov.